Clinical trial
A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in…
NCT00085826 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00085826 |
|---|---|
| Title | A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients |
| Official title | A Phase III, Randomized, Double-Blind, Multi-Center Study of the Efficacy of Taxotere (Docetaxel) in Combination With Aptosyn (Exisulind) Versus Taxotere (Docetaxel) and Placebo in Non-Small Cell Lung Cancer (NSCLC) Patients After Failure of Prior Platinum-Based Chemotherapy |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | OSI Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Exisulind |
| Enrollment | 600 |
| Start date | Apr 1, 2001 |
| Completion | Dec 1, 2004 |
| First posted | Jun 17, 2004 |
| Last update posted | Oct 20, 2011 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: